Pilot Trial of Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

Trial Profile

Pilot Trial of Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Radium 223 chloride (Primary)
  • Indications Bone metastases; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 06 Sep 2017 Planned initiation date changed from 1 Sep 2017 to 1 Nov 2017.
    • 03 Aug 2017 Planned initiation date changed from 1 Aug 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top